aripiprazole has been researched along with Metabolic Syndrome in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (32.00) | 29.6817 |
| 2010's | 14 (56.00) | 24.3611 |
| 2020's | 3 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CK; Chen, CH; Chen, PY; Chiu, CC; Fang, SC; Huang, MC; Hwang, LL; Lu, ML; Mondelli, V | 1 |
| Chen, CH; Chen, PY; Chiu, CC; Hsieh, TH; Huang, CY; Huang, MC; Liu, YR; Lu, ML | 1 |
| Chen, Q; Coid, J; Deng, W; Guo, W; Hu, X; Li, K; Li, L; Li, T; Li, X; Li, Y; Lu, T; Lv, L; Ma, X; Ren, H; Reynolds, GP; Tan, L; Tan, Q; Tian, Y; Wang, C; Wang, H; Wang, L; Wang, Q; Wei, W; Yan, H; Yang, F; Yang, G; Yang, J; Yu, H; Yue, W; Zhang, D; Zhang, F; Zhang, H; Zhang, Y; Zhao, L | 1 |
| Demlova, R; Drazanova, E; Horska, K; Karpisek, M; Kasparek, T; Kotolova, H; Ruda-Kucerova, J | 1 |
| Bolea, B; Davies, S; Ijaz, S; Moran, P; Richards, A; Savović, J; Sullivan, S | 1 |
| Byerly, MJ; Glick, ID; Hamer, RM; Khan, AY; Lamberti, JS; McEvoy, JP; Nasrallah, HA; Ray, N; Steinbook, RM; Stroup, TS | 1 |
| Barbato, A; D'Avanzo, B; Parabiaghi, A; Tettamanti, M | 1 |
| Cocker, KE; Reese, TR; Thiel, DJ | 1 |
| Andrade, C | 1 |
| Kusnir, D; LoPiccolo, M; Sandoz, A; Tausk, FA | 1 |
| Perini, GI; Pigato, G; Toffanin, T | 1 |
| Baker, RA; Kim, E; Meyer, JM; Rosenblatt, LC; Whitehead, R | 1 |
| Baker, RA; Calabrese, JR; Eudicone, JM; Kemp, DE; Pikalov, A; Tran, QV | 1 |
| Kozumplik, O; Sedić, B; Uzun, S | 1 |
| Baker, RA; Chambers, JS; Eudicone, JM; Kemp, DE; McQuade, RD | 1 |
| Ahn, YM; Jung, DC; Kang, UG; Kim, EY; Kim, SH; Kim, YS; Lee, NY; Sung, KH; Yu, HY | 1 |
| Basu, R; Brar, JS; Chang, CC; Ganguli, R; Garbut, R | 1 |
| Arndt, S; Glorioso, DK; Golshan, S; Henry, R; Jeste, DV; Jin, H; Kraemer, HC; Mudaliar, S; Shih, PA | 1 |
| Baker, RA; Carlson, BX; De Hert, M; Eudicone, JM; Fyans, P; Kemp, DE; Marler, SV; Rahman, Z | 1 |
| Ananjit, S; Badiah, Y; Bulgiba, A; Habil, MH; Hairi, NN; Haslina, MY; Hatim, A; Mahmud, B; Ramli, MA; Said, MA; Sapini, Y; Shah, M; Zafidah, W | 1 |
| Kerpel-Fronius, S; Lóránt, M | 1 |
| De Hert, M; Hanssens, L; Peuskens, J; Scheen, A; Van Eyck, D; van Winkel, R; Wampers, M | 1 |
| Correll, CU; Frederickson, AM; Kane, JM; Manu, P | 1 |
| Thomas, P | 1 |
| Carson, WH; Casey, DE; Kan, HJ; L'Italien, GJ; Marcus, RN | 1 |
6 review(s) available for aripiprazole and Metabolic Syndrome
| Article | Year |
|---|---|
Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Polypharmacy; Prospective Studies; Schizophrenia; Systematic Reviews as Topic | 2018 |
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Basal Ganglia Diseases; Behavior Therapy; Benzodiazepines; Cognitive Behavioral Therapy; Dementia; Emotions; Humans; Hypotension, Orthostatic; Metabolic Syndrome; Neuroleptic Malignant Syndrome; Olanzapine; Practice Guidelines as Topic; Psychotic Disorders; Quetiapine Fumarate; Risperidone | 2016 |
Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3: Psychopharmacological Interventions.
Topics: Anti-Obesity Agents; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Fructose; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Schizophrenia; Topiramate | 2016 |
A clinical paradigm of delusions of parasitosis.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Diagnosis, Differential; Female; Humans; Metabolic Syndrome; Middle Aged; Olanzapine; Pain; Patient Compliance; Peripheral Nervous System Diseases; Piperazines; Quinolones; Schizophrenia, Paranoid; Skin Diseases, Parasitic; Sleep Wake Disorders | 2008 |
[A new atypical antipsychotic with partial dopamine agonist effect (aripiprazole)].
Topics: Antipsychotic Agents; Aripiprazole; Controlled Clinical Trials as Topic; Dopamine Agonists; Evidence-Based Medicine; Humans; Meta-Analysis as Topic; Metabolic Syndrome; Piperazines; Quinolones; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists | 2004 |
The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.
Topics: Antipsychotic Agents; Aripiprazole; Chronic Disease; Humans; Metabolic Syndrome; Patient Compliance; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology | 2007 |
7 trial(s) available for aripiprazole and Metabolic Syndrome
| Article | Year |
|---|---|
Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Male; Metabolic Syndrome; Olanzapine; Piperazines; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Triglycerides | 2020 |
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Coronary Artery Disease; Dibenzothiazepines; Drug Substitution; Female; Humans; Longitudinal Studies; Male; Metabolic Syndrome; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone | 2013 |
Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Follow-Up Studies; Haloperidol; Humans; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Schizophrenia; Treatment Outcome | 2016 |
Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Argentina; Aripiprazole; Bipolar Disorder; Comorbidity; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Incidence; Long-Term Care; Male; Metabolic Syndrome; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones | 2010 |
Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Drug Substitution; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Overweight; Piperazines; Quinolones; Schizophrenia; Weight Loss | 2011 |
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Therapeutic Equipoise; Triglycerides; United States | 2013 |
Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lamotrigine; Lithium; Male; Metabolic Syndrome; Middle Aged; Obesity; Overweight; Piperazines; Quinolones; Time Factors; Treatment Outcome; Triazines; Valproic Acid | 2013 |
12 other study(ies) available for aripiprazole and Metabolic Syndrome
| Article | Year |
|---|---|
Orexin-a elevation in antipsychotic-treated compared to drug-free patients with schizophrenia: A medication effect independent of metabolic syndrome.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Diabetes Mellitus, Type 2; Humans; Metabolic Syndrome; Orexins; Prospective Studies; Schizophrenia | 2022 |
The relationship of antipsychotic treatment with reduced brown adipose tissue activity in patients with schizophrenia.
Topics: Adipose Tissue, Brown; Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Metabolic Syndrome; Schizophrenia; Thermogenesis | 2022 |
Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Aripiprazole; Body Weight; Cytokines; Disease Models, Animal; Ghrelin; Glucagon-Like Peptide 1; Leptin; Male; Metabolic Syndrome; Poly I-C; Random Allocation; Rats, Wistar; Schizophrenia | 2017 |
Is a high dosage aripiprazole-clozapine combination an effective strategy for treatment-resistant schizophrenic patients? A case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Resistance; Drug Therapy, Combination; Humans; Male; Metabolic Syndrome; Piperazines; Quinolones; Schizophrenia, Paranoid | 2009 |
The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Black or African American; Blood Glucose; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Hispanic or Latino; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Obesity; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; White People; Young Adult | 2009 |
Changes in values of cholesterol and tryglicerides after weight loss during treatment with aripiprazole in a patient with schizophrenia - Case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol; Croatia; Dose-Response Relationship, Drug; Feeding Behavior; Humans; Life Style; Male; Metabolic Syndrome; Piperazines; Quinolones; Schizophrenia; Triglycerides; Weight Loss | 2010 |
Metabolic syndrome and its potential effect on treatment response to aripiprazole: a post hoc analysis of the stabilization phase of a long-term, double-blind study in patients with bipolar disorder (CN138-010).
Topics: Aripiprazole; Bipolar Disorder; Double-Blind Method; Humans; Metabolic Syndrome; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2010 |
The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Asian People; Benzodiazepines; Cohort Studies; Databases, Factual; Female; Hospitals, University; Humans; Male; Medical Records; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Quinolones; Republic of Korea; Retrospective Studies; Risperidone; Schizophrenia; Sex Factors; Young Adult | 2011 |
Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Cross-Sectional Studies; Female; Flupenthixol; Humans; Malaysia; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quinolones; Schizophrenia; Trifluoperazine; Waist Circumference; Young Adult | 2013 |
A case series: evaluation of the metabolic safety of aripiprazole.
Topics: Adult; Anthropometry; Antipsychotic Agents; Aripiprazole; Belgium; Cohort Studies; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Male; Mass Screening; Metabolic Syndrome; Middle Aged; Piperazines; Prospective Studies; Quinolones; Schizophrenia; Sex Factors; Treatment Outcome | 2007 |
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Mass Index; Cholesterol, HDL; Clozapine; Cross-Sectional Studies; Dibenzothiazepines; Drug Therapy, Combination; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Thiazoles; Triglycerides | 2007 |
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.
Topics: Acute Disease; Adult; Anthropometry; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cholesterol, HDL; Drug Administration Schedule; Female; Humans; Hyperlipidemias; Hypertension; Incidence; Male; Metabolic Syndrome; Olanzapine; Piperazines; Prevalence; Quinolones; Schizophrenia | 2007 |